Amneal Pharmaceuticals announces that it has received the Abbreviated New Drug Application (ANDA) approval from the US FDA for leuprolide acetate for injection. Leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer. The product is available in a 2.8 mL multiple-dose vial.